Please use this identifier to cite or link to this item:
|Title:||Seeking Optimal Management for Radioactive Iodine Therapy-induced Adverse Effects||Authors:||Charalambous, Andreas||Keywords:||Nonpharmacological;Salivary gland side effects;Radioiodine||Category:||Basic Medicine||Field:||Medical and Health Sciences||Issue Date:||1-Oct-2017||Publisher:||EDKNOW PUBLICATIONS & MEDIA PVT LTD||Source:||ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, Volume: 4, Issue: 4, Pages: 319-322,2017||metadata.dc.doi:||http://dx.doi.org/10.4103/apjon.apjon_23_17||Journal:||Asia-Pacific journal of oncology nursing||Abstract:||Radioactive iodine therapy (RAIT) is one of the important treatment modalities in the management of differentiated thyroid cancer (DTC). RAIT with iodine-131 has long been used in the management of DTC for the ablation of residual thyroid or treatment of its metastases. Despite being reasonably safe, radioiodine therapy is not always without side effects. Even relatively low administered activities of RAIT used for remnant ablation have been associated with the more clinically significant side effects of sialadenitis, xerostomia, salivary gland pain and swelling, dry eyes, excessive tearing, or alterations in taste in as many as 25% of patients. Given that there is a lack of comprehensive management of these RAIT-induced adverse effects, this paper explores the use of other nonpharmacological measures and their effectiveness as interventions to minimize salivary gland damage.||URI:||http://ktisis.cut.ac.cy/handle/10488/10513||ISSN:||2347-5625||Rights:||© 2017 Ann & Joshua Medical Publishing Co. Ltd||Type:||Article|
|Appears in Collections:||Άρθρα/Articles|
Show full item record
checked on Dec 13, 2017
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.